• (10/16) Study shows positive results in children with cystic fibrosis and pancreatic insufficiency who are administered Lym-X-Sorb: Two recently published papers showed positive nutritional results compared to placebo when Lym-X-Sorb is administered to children with cystic fibrosis (CF) and pancreatic insufficiency: EFFECT OF ORAL LIPID MATRIX SUPPLEMENT ON FAT ABSORPTION IN CYSTIC FIBROSIS: A RANDOMIZED PLACEBO-CONTROLLED TRIAL and Choline Supplementation With a Structured Lipid in Children With Cystic Fibrosis: A Randomized Placebo-Controlled Trial. Please click here for more information.
  • (7/12) New Patent Issued: BioMolecular Products, Inc. (BMP) announced today the issuance of a patent covering certain molecular structures of its Lym-X-Sorb® (LXS™) technology. The patent, U.S. number 8,222,233, covers claims relating to drug delivery technology and for nutritional supplementation using Lym-X-Sorb's lipid matrix with specified molecular ratios. This brings to nine the number of active U.S. patents surrounding LXS technology held by BMP. Lym-X-Sorb, invented by the late Dr. Yesair, founder of BMP, is an organized lipid matrix that can greatly increase the body's absorption of a number of compounds, including certain drugs, nutrients, and calories. The LXS lipid matrix provides a "lipid glove" protecting and carrying the drug or nutrient to the blood stream, increasing bioavailability and lowering the amount of drug needing to be ingested. Past and ongoing studies have demonstrated its effectiveness.

    Recent studies, conducted under the supervision of researchers at Texas Tech University, have used Lym-X-Sorb in a powderized formulation resembling cookie dough with fenretinide to treat neuroblastoma, solid tumors, and lymphomas. Additionally, a recently completed study, conducted by Avanti Polar Lipids, Inc. and Children's Hospital of Philadelphia with funding from the National institutes of Health, National Diabetes and Digestive and Kidney Division, evaluated Lym-X-Sorb's effectiveness on fatty acid and choline status in children with cystic fibrosis and pancreatic insufficiency. Complete results have not yet been published, although favorable initial abstracts were presented at the 2011 annual meeting of the North American Society for Pediatric Gastroenterology, Hepatalogy, and Nutrition.
  • (10/11) Two abstracts that further demonstrate the efficacy of the Lym-X-Sorb® technology were presented October 20-23, 2011 at the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting. More information on the Nutritional Studies page.
  • (10/11) New Patent Issued: BioMolecular Products, Inc. (BMP) is pleased to announce that it has been awarded a new patent #7947306 Modifications of solid 3-sn-phosphoglycerides. This invention relates to an improved method of phospholipase A 2 hydrolysis of solid ungranulated phosphatidylcholine to produce lysophosphatidylcholine; a method of making a lipid matrix comprising lysophosphatidylcholine, monoglyceride, and fatty acid; as well as lipid matrix compositions having a non-lamellar structure and high viscosity.

Forward-Looking Statements:

To the extent any statements made in these releases contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Line by Line web design